This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Bristol-Myers Squibb Company
Drug Names(s): MDX-1401
Description: MDX-1401 is a fully human antibody that targets CD30. MDX-1401 is enhanced for greater Fc receptor mediated antibody activity, one mechanism in tumor lysis by antibodies.
Deal Structure: MDX-1401 uses BioWa's Potelligent Technology. BioWa is a wholly owned subsidiary of Kyowa Hakko Kogyo.
In July 2009, Bristol-Myers Squibb and Medarex announced that the companies signed a definitive merger agreement providing for the acquisition of Medarex by Bristol-Myers Squibb, for $16.00 per share in cash. The acquisition was completed in September 2009.
Partners: Kyowa Hakko Kirin Co., Ltd.
Pink Sheet UCB Licenses BioWa Antibody Technology
Pink Sheet What Medarex Has To Offer At $2.4 Billion
Additional information available to subscribers only: